<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58829">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072434</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-F-E308</org_study_id>
    <nct_id>NCT02072434</nct_id>
  </id_info>
  <brief_title>Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation</brief_title>
  <acronym>ENSURE-AF</acronym>
  <official_title>A Prospective, Randomized, Open-Label Blinded Endpont Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare edoxaban (investigational drug) with warfarin and
      enoxaparin, to see if it is safe and effective in preventing stroke and other blood clot
      complications in subjects with atrial fibrillation whose doctors plan to treat them with an
      electrical cardioversion.  It is expected that 284 sites will recruit 2200 subjects from
      North America, EU, Russia, Ukraine and Israel.  Participants will be randomly allocated to
      receive either treatment with edoxaban, or treatment with warfarin, plus enoxaparin if
      required. Participants will have an equal chance of receiving either treatment. Participants
      will be in the study for a maximum of 82 days. Study procedures will include physical
      examinations, vital signs (pulse and sitting blood pressure), ECG (electrocardiogram),
      finger prick blood clotting tests, blood samples, urine samples and completion of Quality of
      Life questionnaires.

      The study is expected to show that edoxaban will provide comparable incidence rates for
      efficacy to warfarin plus enoxaparin, the current standard treatment, and will be at least
      as safe as warfarin for the incidence rate for bleeding
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>incidence of composite CV endpoints</measure>
    <time_frame>58 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the incidences of the composite endpoints of stroke, systemic embolic event (SEE), myocardial infarction (MI) and cardiovascular (CV) mortality between the edoxaban group and the enoxaparin/warfarin group from randomization to end of follow up (FU) 58 days post cardioversion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of major and CRNM bleeding</measure>
    <time_frame>61 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare the incidence of the composite endpoints of major and clinically-relevant non-major (CRNM) bleeding between the edoxaban group and the enoxaparin/warfarin group from randomization to end of treatment (58 days post cardioversion) + 3 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of composite CV endpoints and major bleeding</measure>
    <time_frame>58 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare the incidences of the composite endpoints of stroke, systemic embolic event (SEE), myocardial infarction (MI), cardiovascular (CV) mortality and major bleedings between the edoxaban group and the enoxaparin/warfarin group from randomization to end of FU (58 days post cardioversion).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>edoxaban treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Factor Xa inhibitor anticoagulant, oral, edoxaban tablet, 60 or 30 mg QD,28-49 days dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxaparin / warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin K antagonist, sq/oral, 100mg/kg or 1 or 2.5 mg tablet QD, 28-49 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edoxaban</intervention_name>
    <description>Factor Xa inhibitor anticoagulant, oral, edoxaban tablet, 60 or 30 mg once-daily (QD), 28-49 days dosing</description>
    <arm_group_label>edoxaban treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Vitamin K antagonist, sq, 100mg/kg, 28-49 days</description>
    <arm_group_label>enoxaparin / warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Vitamin K antagonist, oral, 1 or 2.5 mg tablet QD, 28-49 days</description>
    <arm_group_label>enoxaparin / warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Male or female older than minimum legal adult age (country specific)

          -  Ongoing AF lasting at least 48 hrs but &lt;= 12 months

        Exclusion Criteria:

          -  .AF that is transient or reversible

          -  No other rhythm issues other than AF

          -  Mitral stenosis or rheumatic disease, unresected atrial myxoma or mechanical heart
             valve

          -  Left atrial appendage closure or thrombus

          -  MI, stroke, ACS, PCI within 30 days

          -  High risk of bleeding within 10 days or randomization

          -  Dual antiplatelet therapy

          -  List of prohibited concomitant medication

          -  Active liver disease

          -  Renal failure, CrCl &lt; 15 ml/min

          -  Hemoglobin &lt; 10g/dl or platelet count &lt; 100000 cells/microliter

          -  Taking other investigational drugs

          -  Women of childbearing potential with proper contraceptives measures

          -  Active cancer requiring chemotherapy/radiation/surgery

          -  Investigator discretion based on examination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Goette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kardiologie und Internistische Intensivmedizin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cain Price</last_name>
    <phone>44-162854-8000</phone>
    <email>cain.price@covance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuk-Fung Keane</last_name>
    <phone>44-162854-8000</phone>
    <email>yuk-fung.keane@covance.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ephrata</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.</citation>
    <PMID>24251359</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>anti-coagulant</keyword>
  <keyword>warfarin</keyword>
  <keyword>edoxaban</keyword>
  <keyword>electrical cardioversion</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
